Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsQualChoice Baxdrostat Prior Auth Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentQualChoicePolicy CP.PHAR.792

    Baxdrostat (Baxfendy)

    Customize your policy alerts

    Sign up for QualChoice Policy CP.PHAR.792 alerts

    Get alerted when Policy CP.PHAR.792 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and medical-necessity coverage for Baxdrostat (Baxfendy) used with other antihypertensive drugs to treat hypertension in adults across commercial, HIM/ICHRA, and Medicaid lines of business.

    Policy Summary
    PayerQualChoice
    PolicyBaxdrostat (Baxfendy)
    Policy CodePolicy CP.PHAR.792
    Change TypeNo material change
    Effective DateSep 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit clinical documentation demonstrating that all applicable Baxfendy approval criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsApproval duration
    2 mg/dayMaximum dose
    1 tablet/dayMaximum quantity
    3 or 4Required drug classes
    18 yearsMinimum age

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Initial therapy — hypertension

    Covered for hypertension when all of the following criteria are met:

    Initial hypertension approval

    • Diagnosis: Member has a diagnosis of hypertension.
    • Age: Member is at least 18 years old.Age ≥ 18 years
    • Recent blood pressure: A blood pressure measurement is documented within the last 30 days.Within the last 30 days
    • Blood-pressure pathway

      • BP ≥ 130/80 mmHg

        • Baxfendy is prescribed concurrently with an antihypertensive regimen containing three or more drug classes, unless clinically significant adverse effects are experienced or all are contraindicated.
        • Member has been adherent for at least the last 4 weeks at up to maximally tolerated doses of an antihypertensive regimen containing at least three different antihypertensive drug classes.
      • BP < 130/80 mmHg

        • Baxfendy is prescribed concurrently with an antihypertensive regimen containing four or more drug classes, unless clinically significant adverse effects are experienced or all are contraindicated.
        • Member has been adherent for at least the last 4 weeks at up to maximally tolerated doses of an antihypertensive regimen containing at least four different antihypertensive drug classes.
    • Dose limit: The dose does not exceed 2 mg per day and 1 tablet per day.≤ 2 mg/day and ≤ 1 tablet/day

    Other diagnoses or indications

    Other diagnoses or indications must meet one of the following pathways:

    • Recent label-change pathway

      • Formulary or PDL drug: If the drug has undergone a label change within the last 6 months that is not yet reflected in this policy and the drug is on the formulary or PDL, refer to the applicable no-coverage criteria policy: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, or CP.PMN.255 for Medicaid.
      • Drug not on formulary or PDL: If the drug has undergone a label change within the last 6 months that is not yet reflected in this policy and the drug is not on the formulary or PDL, refer to the applicable non-formulary policy: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, or CP.PMN.16 for Medicaid.
    • Off-label pathway

      • The requested use is not specifically listed under the diagnoses or indications for which coverage is not authorized.

    Continuation therapy — hypertension

    Covered for continuation of hypertension therapy when all of the following criteria are met:

    Continuation hypertension approval

    • Qualifying therapy status

      • Member is currently receiving Baxfendy through the Centene benefit or previously met the initial approval criteria.
      • Member is currently receiving Baxfendy and is enrolled in a state and product subject to continuity-of-care regulations.

        Refer to the applicable state-specific addenda CC.PHARM.03A and CC.PHARM.03B.

    • Treatment response: Member is responding positively to therapy.
    • Dose increase limit: If the request is for a dose increase, the new dose does not exceed 2 mg per day and 1 tablet per day.

    Non-FDA-approved indications that are not addressed in this policy are not authorized for coverage unless sufficient documentation of efficacy and safety supports the request under the applicable off-label use policy or evidence of coverage documents.

    For Medicaid members, state Medicaid coverage provisions take precedence when they conflict with this clinical policy. Refer to the applicable state Medicaid manual for coverage provisions related to this policy.

    Clinical and Quantity Parameters

    Three-Class Regimen
    Blood pressure thresholdBP ≥ 130/80 mmHg
    Concurrent regimenAt least three antihypertensive drug classes
    Adherence requirementAt least the last 4 weeks at up to maximally tolerated doses
    Four-Class Regimen
    Blood pressure thresholdBP < 130/80 mmHg
    Concurrent regimenAt least four antihypertensive drug classes
    Adherence requirementAt least the last 4 weeks at up to maximally tolerated doses
    Recent Blood Pressure
    Required timingWithin the last 30 days
    Clinical measureBlood pressure
    Documentation contextA recent blood pressure must be documented for initial approval
    Antihypertensive Adherence
    Minimum periodAt least the last 4 weeks
    TherapyAntihypertensive drug regimen
    Dose levelUp to maximally tolerated doses
    Baxfendy Maximum Dose
    Maximum dose2 mg per day
    Administration2 mg PO QD
    Continuation requestsA requested dose increase must not exceed 2 mg per day
    Baxfendy Maximum Quantity
    Maximum quantity1 tablet per day
    Initial approvalThe dose must not exceed 1 tablet per day
    Continuation requestsA requested dose increase must not exceed 1 tablet per day

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Baxfendy. The provider must submit clinical documentation demonstrating that the member meets all applicable initial or continuation approval criteria.

    Prior Authorization

    Renewal Authorization

    Continuation requests require documentation that the member qualifies for ongoing therapy and is responding positively to Baxfendy. Approval is limited to 12 months; dose increases must remain within the policy limits.

    • Member is currently receiving Baxfendy through the Centene benefit or previously met initial approval criteria, or is receiving therapy under applicable state and product continuity-of-care regulations.
    • Document positive response to therapy.
    • Approval duration: 12 months.
    • Any requested dose increase must not exceed 2 mg per day and 1 tablet per day.
    Documentation Required

    Three-Class Antihypertensive Regimen

    For members with blood pressure at or above 130/80 mmHg, Baxfendy must be prescribed concurrently with an antihypertensive regimen containing at least three drug classes, unless clinically significant adverse effects are experienced or all such therapies are contraindicated.

    • Document adherence for at least the preceding 4 weeks at up to maximally tolerated doses of a regimen containing at least three different antihypertensive drug classes.
    Documentation Required

    Four-Class Antihypertensive Regimen

    For members with blood pressure below 130/80 mmHg, Baxfendy must be prescribed concurrently with an antihypertensive regimen containing at least four drug classes, unless clinically significant adverse effects are experienced or all such therapies are contraindicated.

    • Document adherence for at least the preceding 4 weeks at up to maximally tolerated doses of a regimen containing at least four different antihypertensive drug classes.
    Documentation Required

    Clinical Documentation

    Submit chart notes, laboratory results, or other clinical information supporting that the member has met all applicable Baxfendy approval criteria.

    • Documentation must support the diagnosis, blood pressure, antihypertensive regimen, adherence, therapy status, response, dose, and any applicable exception or contraindication.
    Documentation Required

    Initial Hypertension Documentation

    For initial hypertension approval, documentation must establish all required clinical elements before Baxfendy is authorized.

    • Diagnosis of hypertension.
    • Member is at least 18 years of age.
    • Recent blood pressure documented within the last 30 days.
    • Concurrent antihypertensive regimen and qualifying three-class or four-class requirement based on blood pressure.
    • Adherence for at least 4 weeks at up to maximally tolerated doses, unless clinically significant adverse effects are experienced or all applicable therapies are contraindicated.
    • Dose does not exceed 2 mg per day and 1 tablet per day.
    • Approval duration: 12 months.
    Documentation Required

    Continuation Documentation

    For continuation approval, document that the member remains eligible for Baxfendy therapy and is responding positively to treatment.

    • Current therapy through the Centene benefit or prior satisfaction of initial approval criteria, or current therapy under applicable continuity-of-care regulations.
    • Positive response to therapy.
    • For a dose increase, the requested dose must not exceed 2 mg per day and 1 tablet per day.
    Denial Risk

    Non-FDA-Approved Indications

    Coverage is not authorized for non-FDA-approved indications that are not addressed by this policy unless sufficient documentation of efficacy and safety supports the off-label use under the applicable policy or evidence of coverage documents.

    • Applicable references may include CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.
    Denial Risk

    Failure to Meet Initial Hypertension Criteria

    Initial hypertension requests may be denied when any required approval element is absent or unsupported.

    • Member is younger than 18 years or lacks a documented diagnosis of hypertension.
    • Recent blood pressure is not documented within the last 30 days.
    • The concurrent antihypertensive regimen does not contain at least three drug classes when BP is at least 130/80 mmHg, or at least four drug classes when BP is below 130/80 mmHg, without a documented adverse-effect or contraindication exception.
    • Adherence for at least the preceding 4 weeks at up to maximally tolerated doses is not demonstrated.
    • Requested dose exceeds 2 mg per day or 1 tablet per day.
    • Other required clinical documentation is missing or does not support the criteria.
    Denial Risk

    Failure to Meet Continuation Criteria

    Continuation requests may be denied when qualifying therapy status or positive response is not documented, or when the requested dose exceeds policy limits.

    • Member is not currently receiving Baxfendy through the Centene benefit, has not previously met initial criteria, and is not covered by applicable continuity-of-care regulations.
    • Member is not responding positively to therapy.
    • Requested dose increase exceeds 2 mg per day or 1 tablet per day.

    Drug Background

    Baxdrostat (Baxfendy) is an aldosterone synthase inhibitor indicated for use in combination with other antihypertensive drugs to lower blood pressure in adults whose hypertension is not adequately controlled with other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.

    Policy Definitions

    Definitions
    TermBaxdrostat
    DefinitionAn aldosterone synthase inhibitor
    Brand nameBaxfendy
    Definitions
    AbbreviationFDA
    Full nameFood and Drug Administration
    Reference locationAppendix A: Abbreviation/Acronym Key
    Definitions
    TermHealth Plan
    AdoptionA health plan that has adopted this clinical policy
    AdministrationOperated or administered, in whole or in part, by Centene Management Company, LLC, or one of its applicable health-plan affiliates

    Initial Baxfendy Therapy

    Baxfendy initial hypertension therapy

    Initial Baxfendy therapy for hypertension is covered when all of the following criteria are met:

    Initial Baxfendy therapy

    • Member has a diagnosis of hypertension.
    • Member is at least 18 years old.Age ≥ 18 years
    • A blood pressure measurement is documented within the last 30 days.Within the last 30 days
    • Applicable antihypertensive regimen and adherence pathway

      • BP ≥ 130/80 mmHg

        • Baxfendy is prescribed concurrently with an antihypertensive regimen containing three or more drug classes, unless clinically significant adverse effects are experienced or all are contraindicated.
        • Member has been adherent for at least the last 4 weeks at up to maximally tolerated doses of an antihypertensive regimen containing at least three different antihypertensive drug classes.
      • BP < 130/80 mmHg

        • Baxfendy is prescribed concurrently with an antihypertensive regimen containing four or more drug classes, unless clinically significant adverse effects are experienced or all are contraindicated.
        • Member has been adherent for at least the last 4 weeks at up to maximally tolerated doses of an antihypertensive regimen containing at least four different antihypertensive drug classes.
    • The dose does not exceed 2 mg per day and 1 tablet per day.≤ 2 mg/day and ≤ 1 tablet/day

    Continuation of Baxfendy Therapy

    Baxfendy continuation

    Continuation Baxfendy therapy is covered when all of the following criteria are met:

    Continuation therapy

    • Qualifying current or prior therapy status

      • Member is currently receiving Baxfendy through the Centene benefit or previously met the initial approval criteria.
      • Member is currently receiving Baxfendy and is enrolled in a state and product subject to continuity-of-care regulations.

        Refer to the applicable state-specific addenda CC.PHARM.03A and CC.PHARM.03B.

    • Member is responding positively to therapy.
    • If the request is for a dose increase, the new dose does not exceed 2 mg per day and 1 tablet per day.≤ 2 mg/day and ≤ 1 tablet/day

    Required Antihypertensive Regimens

    StepBlood pressureConcurrent antihypertensive regimenAdherence requirement
    1BP ≥ 130/80 mmHgBaxfendy prescribed concurrently with a regimen containing three or more antihypertensive drug classes, unless clinically significant adverse effects are experienced or all are contraindicated.Adherent for at least the last 4 weeks at up to maximally tolerated doses of a regimen containing at least three different antihypertensive drug classes.
    StepBlood pressureConcurrent antihypertensive regimenAdherence requirement
    2BP < 130/80 mmHgBaxfendy prescribed concurrently with a regimen containing four or more antihypertensive drug classes, unless clinically significant adverse effects are experienced or all are contraindicated.Adherent for at least the last 4 weeks at up to maximally tolerated doses of a regimen containing at least four different antihypertensive drug classes.

    Baxfendy Dose and Quantity Limits

    Quantity Limits
    DrugBaxfendy
    Maximum dose2 mg per day
    Administration2 mg PO QD
    Quantity Limits
    DrugBaxfendy
    Maximum quantity1 tablet per day
    Applies toInitial therapy and requested continuation dose increases
    Policy Summary
    PayerQualChoice
    PolicyBaxdrostat (Baxfendy)
    Policy CodePolicy CP.PHAR.792
    Change TypeNo material change
    Effective DateSep 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit clinical documentation demonstrating that all applicable Baxfendy approval criteria are met.
    SourceLink
    On This Page
    Coverage CriteriaClinical and Quantity ParametersAuthorization and Documentation RequirementsDrug BackgroundPolicy DefinitionsInitial Baxfendy TherapyContinuation of Baxfendy TherapyRequired Antihypertensive RegimensBaxfendy Dose and Quantity Limits
  1. The recent label-change pathway does not apply.
  2. Refer to the applicable off-label use policy: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, or CP.PMN.53 for Medicaid.
  3. ≤ 2 mg/day and ≤ 1 tablet/day